4.7 Review

Plastin 3 in health and disease: a matter of balance

Journal

CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 78, Issue 13, Pages 5275-5301

Publisher

SPRINGER BASEL AG
DOI: 10.1007/s00018-021-03843-5

Keywords

Cutaneous T-cell lymphomas; Colorectal cancer; Osteoclasts; Amyotrophic lateral sclerosis; Ataxia

Funding

  1. German Research Foundation [Wi 945/17-1, FOR2722, 407176282, SFB 1451, 431549029A01, GRK1960, 233886668]
  2. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [956185]
  3. Center for Molecular Medicine Cologne [C18]
  4. Koln Fortune MD candidate fellowship
  5. Project DEAL
  6. Marie Curie Actions (MSCA) [956185] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

PLS3, previously considered as a less important actin-binding protein, has now been found to play crucial roles in various cellular processes, signaling pathways, and diseases. Its expression variability due to skewed X-inactivation can lead to cancer, while its upregulation may be protective in spinal muscular atrophy. Precise balance of PLS3 levels is critical as both deficiency and excess can have detrimental effects on health.
For a long time, PLS3 (plastin 3, also known as T-plastin or fimbrin) has been considered a rather inconspicuous protein, involved in F-actin-binding and -bundling. However, in recent years, a plethora of discoveries have turned PLS3 into a highly interesting protein involved in many cellular processes, signaling pathways, and diseases. PLS3 is localized on the X-chromosome, but shows sex-specific, inter-individual and tissue-specific expression variability pointing towards skewed X-inactivation. PLS3 is expressed in all solid tissues but usually not in hematopoietic cells. When escaping X-inactivation, PLS3 triggers a plethora of different types of cancers. Elevated PLS3 levels are considered a prognostic biomarker for cancer and refractory response to therapies. When it is knocked out or mutated in humans and mice, it causes osteoporosis with bone fractures; it is the only protein involved in actin dynamics responsible for osteoporosis. Instead, when PLS3 is upregulated, it acts as a highly protective SMN-independent modifier in spinal muscular atrophy (SMA). Here, it seems to counteract reduced F-actin levels by restoring impaired endocytosis and disturbed calcium homeostasis caused by reduced SMN levels. In contrast, an upregulation of PLS3 on wild-type level might cause osteoarthritis. This emphasizes that the amount of PLS3 in our cells must be precisely balanced; both too much and too little can be detrimental. Actin-dynamics, regulated by PLS3 among others, are crucial in a lot of cellular processes including endocytosis, cell migration, axonal growth, neurotransmission, translation, and others. Also, PLS3 levels influence the infection with different bacteria, mycosis, and other pathogens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available